ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1615

MiR-127-3p As a Novel Regulator of Type I Interferon Signaling Pathway in SLE

Bo Qu1,2, Xiao Han2 and Nan Shen1,2,3, 1Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, 2Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, Shanghai, China, 3The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Kidney, MicroRNA, SLE and interferons

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies

Session Type: Abstract Submissions (ACR)

Background/Purpose

Type I interferon(IFN) is a critical pathogenic factor in Systemic Lupus Erythematosus(SLE) and its associated nephritis, as elevated IFN inducible genes have been found in the kidney tissues and deficiency of IFN receptor protects lupus mouse model from developing nephritis. Reduced miR-146a is in part the reason for uncontrolled IFN response in peripheral blood cells of SLE. However, we are not clear if there are abnormally expressed kidney miRNAs that are responsible for the overactivated IFN response in the renal tissue of SLE. Our previous miRNA profiling data showed that miR-127-3p was one of the most reduced miRNAs in renal biopsies of lupus nephritis patients, raising the question whether miR-127-3p plays a role in IFN signaling. In this study, we explored the regulatory function of miR-127-3p in IFN signaling and its therapeutic effects on SLE.

Methods

miR-127-3p was quantified by RT-qPCR. Interferon-stimulated response element(ISRE)-luciferase reporter assay and western blotting were used to investigate the function of miR-127-3p. Genes affected by miR-127-3p were identified by microarray. Antagomir(chemical modified miRNA inhibitors) was used to inhibit the function of miR-127-3p to validate its function. We administrated agomir(chemical modified miRNA mimics) into pristane induced lupus mouse model to investigate the in vivo function of miR-127-3p.

Results

To test its function in IFN signaling, we transfected miR-127-3p together with ISRE-luciferase reporter plasmids into Hela cells and then stimulated the cells with IFN. We found that miR-127-3p inhibited IFN mediated expression of the reporter gene. Consistently, miR-127-3p inhibited IFN induced phosphorylation of STAT1 and STAT2, which are two major upstream molecules that activate ISRE mediated gene expression. We further revealed that most of the IFN inducible genes were inhibited by miR-127-3p in Hela cells. In addition, in human primary renal mesangial cells, loss of function of miR-127-3p augmented IFN signaling including enhanced ISRE mediated reporter gene expression, stronger phosphorylation of STAT2 and elevated expression of IFN inducible genes. By Ribonucleoprotein ImmunoPrecipitation assay, we identified JAK1, the upstream tyrosine kinase of STAT1 and STAT2, as the target of miR-127-3p. To elucidate the mechanism of reduced miR-127-3p, we screened several inflammatory factors and found that IFN inhibited miR-127-3p in renal cells. What’s more, we injected IFN into the mice and found that IFN inhibited the expression of miR-127-3p in their kidneys. To test its therapeutic effects, we examined a short-term phenomenon, pulmonary hemorrhage(PH), in pristane induced lupus mouse model and found that administrating miR-127-3p alleviated PH and inhibited IFN inducible gene Mx1 in peripheral blood cells.

Conclusion

Our study shows renal miR-127-3p can inhibit IFN signaling, indicating a new mechanism of overactivated IFN response in the kidney of SLE. Preliminary in vivo data suggest miR-127-3p has therapeutic potential in SLE. Ongoing mouse model studies about the effects of miR-127-3p on lupus nephritis will give us more insights into its therapeutic value.


Disclosure:

B. Qu,
None;

X. Han,
None;

N. Shen,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mir-127-3p-as-a-novel-regulator-of-type-i-interferon-signaling-pathway-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology